Promising kidney drug trial for alport syndrome halted early
NCT ID NCT02855268
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 35 times
Summary
This study tested a weekly injection called lademirsen in 43 adults with Alport syndrome, a genetic condition that damages kidneys. The goal was to see if the drug could slow the loss of kidney function and check for side effects. The trial was stopped early, but the results help researchers understand how to better treat this rare disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center_Investigational Site Number :8400004
New York, New York, 10032, United States
-
Investigational Site Number :0360001
Parkville, Victoria, 3050, Australia
-
Investigational Site Number :0360002
Nedlands, Western Australia, 6009, Australia
-
Investigational Site Number :0360003
Herston, Queensland, 4029, Australia
-
Investigational Site Number :1560001
Beijing, 100034, China
-
Investigational Site Number :1560002
Beijing, 100730, China
-
Investigational Site Number :1560004
Guangzhou, 510080, China
-
Investigational Site Number :2500001
Paris, 75015, France
-
Investigational Site Number :2500002
Toulouse, 31403, France
-
Investigational Site Number :7240001
Barcelona, Barcelona [Barcelona], 08025, Spain
-
Investigational Site Number :7240002
Madrid / Madrid, Madrid, Comunidad de, 28040, Spain
-
Investigational Site Number :7240003
Granada, 18014, Spain
-
Investigational Site Number :7240004
Barcelona, Barcelona [Barcelona], 08035, Spain
-
Investigational Site Number :7240005
Córdoba, Andalusia, 14004, Spain
-
Investigational Site Number :8260001
London, London, City of, NW3 2QG, United Kingdom
-
Investigational Site Number :8260002
Nottingham, Nottinghamshire, NG5 1PB, United Kingdom
-
Investigational Site Number :8260003
Newcastle upon Tyne, NE7 7DN, United Kingdom
-
Investigational Site Number :8400002
Los Angeles, California, 90024, United States
-
The Cleveland Clinic Foundation_Investigational Site Number :8400001
Cleveland, Ohio, 44195, United States
-
Uniklinik Köln, Innere Medizin II - Nephrologie, Rheumatologie, Diabetologie und Allgemeine Innere Medizin_Investigational Site Number :2760001
Cologne, 50937, Germany
-
University of Minnesota Childrens' Hospital_Investigational Site Number :8400003
Minneapolis, Minnesota, 55454, United States
-
University of Utah_Investigational Site Number :8400005
Salt Lake City, Utah, 84132, United States
-
Universitätsmedizin Göttingen, Klinik für Nephrologie und Rheumatologie_Investigational Site Number :2760002
Göttingen, 37075, Germany
Conditions
Explore the condition pages connected to this study.